OneSource Specialty Pharma Limited ONESOURCE NIFTY_SMALLNSEPHARMA
Company Overview
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed pens, and autoinjectors and self-administration platforms; sterile injectables; soft gelatin capsules; and biologics solutions for recombinant proteins, monoclonal antibodies and biosimilars, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Why Investors Should Care
Net profit has compounded at 30.3% per year over the last five years.
Revenue has grown at a 232.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.26.
Recent Developments
- Mar 2026 Revenue of ₹1,421.59 Cr (-1.6% YoY); net profit ₹-73.80 Cr.
- Trailing 12 Months Year-on-year growth — revenue +37.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 232.4%, profit CAGR 30.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 232.38% |
| 1 Year: | 37.20% |
Compounded Profit Growth
| 5 Years: | 30.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -28.57% |
| 6 Months: | -25.61% |
| 3 Months: | -18.81% |
| 1 Month: | -14.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.01 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 232.4% over 5 years.
- Profit CAGR of 30.3% over 5 years.
CONS
- Trading 28.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONESOURCE OneSource Specialty Pharma Limited NIFTY_SMALLNSEPHARMA | 1,357.10 | -319.32 | ₹15,562.38 Cr | 0.00% | 0.45% | -1.27% | 232.38% | 30.26% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.71 Cr | 56.21 Cr | 73.14 Cr | 292.29 Cr | 334.05 Cr | 392.56 Cr | - | 327.27 Cr | 375.76 Cr | 290.34 Cr | 428.22 Cr | 449.02 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | 92.92 Cr | 113.49 Cr | 94.37 Cr | 146.26 Cr | 142.32 Cr |
| Gross Profit | - | - | - | - | - | - | - | 234.35 Cr | 262.27 Cr | 195.97 Cr | 281.95 Cr | 306.70 Cr |
| Operating Expenses | 72.22 Cr | 66.71 Cr | 75.94 Cr | 228.00 Cr | 256.75 Cr | 250.68 Cr | - | 213.67 Cr | 225.60 Cr | 248.29 Cr | 261.86 Cr | 255.10 Cr |
| Operating Income | -56.94 Cr | -30.03 Cr | -22.33 Cr | -4.06 Cr | 9.02 Cr | 73.11 Cr | - | 20.68 Cr | 36.67 Cr | -52.31 Cr | 20.09 Cr | 51.60 Cr |
| EBITDA | -38.51 Cr | -10.50 Cr | -2.80 Cr | 64.29 Cr | 77.30 Cr | 141.88 Cr | - | 90.88 Cr | 109.53 Cr | 14.86 Cr | 94.05 Cr | 122.85 Cr |
| Interest Expense | 24.55 Cr | 26.01 Cr | 20.46 Cr | 42.05 Cr | 45.05 Cr | 45.82 Cr | - | 27.48 Cr | 33.96 Cr | 38.23 Cr | 22.51 Cr | 30.81 Cr |
| Pretax Income | -113.73 Cr | -130.17 Cr | -40.17 Cr | -46.62 Cr | -37.45 Cr | -66.51 Cr | - | -4.40 Cr | 5.74 Cr | -93.01 Cr | -29.20 L | 20.29 Cr |
| Tax Provision | -0 | -0 | -0 | 41.07 Cr | -4.63 Cr | -2.35 Cr | - | -4.21 Cr | -4.74 Cr | -4.31 Cr | -4.89 Cr | -4.70 Cr |
| Net Income | -113.73 Cr | -130.16 Cr | -40.17 Cr | -5.55 Cr | -42.08 Cr | -68.85 Cr | - | -18.60 L | 10.48 Cr | -88.70 Cr | 4.60 Cr | 25.00 Cr |
| Diluted EPS | - | - | - | - | - | -6.02 | - | -0.02 | 0.91 | -7.74 | 0.40 | 2.18 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 21.00 Cr | 128.00 Cr | 38.71 Cr | 171.92 Cr | 1,444.85 Cr | 1,421.59 Cr |
| Cost of Revenue | - | - | 20.41 Cr | 70.51 Cr | 435.03 Cr | 444.65 Cr |
| Gross Profit | - | - | 18.30 Cr | 101.41 Cr | 1,009.82 Cr | 976.94 Cr |
| Operating Expenses | 93.00 Cr | 132.00 Cr | 234.19 Cr | 257.94 Cr | 817.19 Cr | 951.81 Cr |
| Operating Income | -105.00 Cr | -57.00 Cr | -215.88 Cr | -156.53 Cr | 192.63 Cr | 25.13 Cr |
| EBITDA | -71.00 Cr | -4.00 Cr | -261.44 Cr | -184.92 Cr | 373.14 Cr | 309.32 Cr |
| Interest Expense | 16.00 Cr | 46.00 Cr | 40.11 Cr | 85.40 Cr | 166.32 Cr | 122.19 Cr |
| Pretax Income | -121.00 Cr | -231.00 Cr | -415.64 Cr | -365.70 Cr | -67.07 Cr | -91.96 Cr |
| Tax Provision | -0 | 0 | 0 | 0 | -49.78 Cr | -18.16 Cr |
| Net Income | -121.00 Cr | -231.00 Cr | -799.83 Cr | -391.17 Cr | -17.97 Cr | -73.80 Cr |
| Diluted EPS | - | - | -69.89 | -34.18 | -1.63 | -6.44 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | 1,258.00 Cr | 2,442.00 Cr | 2,008.81 Cr | 1,308.61 Cr | 7,550.24 Cr | 8,210.01 Cr |
| Current Assets | - | - | 228.40 Cr | 176.38 Cr | 1,086.18 Cr | 1,425.94 Cr |
| Cash & Equivalents | - | - | 4.97 Cr | 6.47 Cr | 156.48 Cr | 35.68 Cr |
| Inventory | - | - | 133.16 Cr | 11.23 Cr | 158.06 Cr | 438.96 Cr |
| Receivables | - | - | 3.82 Cr | 55.24 Cr | 416.60 Cr | 690.22 Cr |
| Total Liabilities | - | - | 1,223.36 Cr | 912.90 Cr | 1,669.66 Cr | 2,378.72 Cr |
| Current Liabilities | - | - | 865.22 Cr | 630.59 Cr | 1,113.56 Cr | 1,441.97 Cr |
| Long Term Debt | - | - | 334.88 Cr | 271.59 Cr | 219.33 Cr | 563.70 Cr |
| Total Debt | 386.00 Cr | 1,182.00 Cr | 864.22 Cr | 571.17 Cr | 942.44 Cr | 1,503.94 Cr |
| Total Equity | 776.00 Cr | 1,012.00 Cr | 785.45 Cr | 395.71 Cr | 5,880.58 Cr | 5,831.29 Cr |
| Shares Outstanding | - | - | 11.44 Cr | 11.44 Cr | 11.44 Cr | 11.46 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -118.00 Cr | -416.00 Cr | -162.76 Cr | -107.21 Cr | -67.85 Cr | 8.52 Cr |
| Investing Cash Flow | -207.00 Cr | -692.00 Cr | -67.83 Cr | 510.55 Cr | -201.08 Cr | -494.98 Cr |
| Financing Cash Flow | 381.00 Cr | 1,162.00 Cr | 118.32 Cr | -390.54 Cr | 412.01 Cr | 359.44 Cr |
| Capital Expenditure | -207.00 Cr | -655.00 Cr | -43.99 Cr | -63.77 Cr | -128.15 Cr | -569.07 Cr |
| Free Cash Flow | -325.00 Cr | -1,071.00 Cr | -206.76 Cr | -170.98 Cr | -196.00 Cr | -560.55 Cr |
| Net Change in Cash | 56.00 Cr | 54.00 Cr | -112.28 Cr | 12.79 Cr | 143.07 Cr | -127.02 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 47.3% | 59.0% | 69.9% | 68.7% |
| Operating Margin % | -500.0% | -44.5% | -557.6% | -91.0% | 13.3% | 1.8% |
| Net Margin % | -576.2% | -180.5% | -2,066.0% | -227.5% | -1.2% | -5.2% |
| ROE % | -15.6% | -22.8% | -101.8% | -98.9% | -0.3% | -1.3% |
| ROCE % | - | - | -18.9% | -23.1% | 3.0% | 0.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONESOURCE
Are Auto-Tires-Trucks Stocks Lagging Custom Truck One Source (CTOS) This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWlI5VHlCVkhjZ0ZKNWJ0NlZQZWx5ajhVaG1wOXFHZHR6eXBHaWMtaTdObTlvR3lMYUQyelhuUlZfcW5YbHlfTG5JWW5TZWJkNDJHVEdxNFZLYXN5Z3VaRGNHR01KUmlfbGR3VUdFbHFOaXdmVHdob3N6VFpiWlhRYVFaM185Q2V4SFY0UX…
FTAI Aviation, Custom Truck One Source, EMCOR, Caterpillar, and Alta Stocks Trade Up, What You Need To Know - TradingView
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxQV3RXeGxFdDYzZ0ZFYzFHa0FmSHdEWXlJc1FGQXNlRnliNWFQRlhCNDNOdF95U0ZWQ0V2TVJqQTZrQW5oend0Z29mbW9EZ1R6M3ZzY0hWajJRWHRkSDM1YUdqY0k2R2R4SGNmdkh6b0RrVkJpN0FlRDRuU0ZjbHZEelpBeVNVcnN0Qmxhan…
OneSource Specialty Pharma (NSEI:ONESOURCE) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNdjcydTRPNEw2RXFWSm1BOUdsR0QwQlo2dHNjVkF5ZTR5eEpUcWZ3S08xQ1BWdlRfVDJvRm1FTGR1YjN1Q0lmdmhjRTBCVkttLXpZY0VsMEl6MXBmcmMtbW1rcEdvaUxSSVNOcGY0cU91TmJ1VEx4elo0WHFuR2xOTDU0eGhhZUJTS05ZVU…
OneSource Specialty Pharma stock: what the FY28 bet rests on - Value Research
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUkhkRkt5aGxWbC1IM1RiWTVEVVBmS1ktdnhBYzBJazk0SVMya2RGZ3I3UG1DSWJQQk9xUEVIbkFKcWNqeEo2UDh0NG5vdXp1UjEwa3VoWG5kaFg0ZWpiV3JqM2MzVS1Ra1ZHb3FfWmxZU3U3dmlvQ2lqOXl3Q3U4RGRKTHQ4clpvSGRzV0…
D.A. Davidson reiterates Custom Truck One Source stock rating on bullish outlook - Investing.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQRjhsNDNWRFlMRFNjYkNDeUxlczJncXg5YmhRYjhjM3h6am9nTW5mQTF3dHRDWnlhZVpEcDZfTUM1dmNhS2g0VHk1ZjB1c2NPTUtqM3YzTEw1Y0d3LUwtNDNOSGVWa2QtejNRc2NiODRQdEoweW5KQVhhTVYwU0ZmUFU3aGxOcVM0Z2JLR3…
Custom Truck One Source, Terex, Xylem, Onterris, and Oshkosh Shares Plummet, What You Need To Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOQ3dNcTVfYzd6OThmbkxyc0pDS1laWTFfa0ZkVlNXOGdtRE5Zb2xhVmU1d0NTZW9VMmdYYUlrb0N5VzhPekRSTWJEMnhHenhGcjlhQnpWTXYyODVxZ0FFR2hLYy1PaERkT1RYbnRzSS1jdmV2bTNaTHp1ODVFU0NDaHJsMU9MV25KRGpfaj…
ONESOURCE — Frequently Asked Questions
What is the current share price of OneSource Specialty Pharma Limited (ONESOURCE)?
As of 2026-10-23 04:58 IST, OneSource Specialty Pharma Limited (ONESOURCE) trades at ₹1,357.10 on NSE. Its 52-week range is ₹1,114.00 to ₹1,899.90.
What is the market capitalisation of ONESOURCE?
OneSource Specialty Pharma Limited (ONESOURCE) has a market capitalisation of ₹15,562.38 Cr on NSE.
What is the P/E ratio of ONESOURCE?
ONESOURCE trades at a trailing price-to-earnings (P/E) ratio of -319.32. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.88.
What is the return on equity (ROE) of ONESOURCE?
ONESOURCE has a return on equity (ROE) of -1.27%. Its return on capital employed (ROCE) is 0.45%.
Is ONESOURCE a good stock to buy?
This page provides a data-driven analysis of OneSource Specialty Pharma Limited (ONESOURCE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.